A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

NCT02622321 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Emicizumab
DRUG: rFVIIa
DRUG: aPCC

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]